042IC - Genetics and Genomics of GU Malignancies - Applications into Your Clinical Practice

Saturday, April 29, 2023

4:00 PM – 6:00 PM CST

Location: S102B

Instructional Course Director(s)

Hong Truong, MD,MS

Penn State Health Milton S. Hershey Medical Center

Instructional Course Faculty(s)

Maria Baker, PhD

Professor of Medicine
Penn State College of Medicine
Maria Carlo, MD

Memorial Sloan Kettering Cancer Center
Brian Shuch, MD

David Geffen School of Medicine at UCLA

Course Description:This case-based interactive course reviews the role of germline genetics in genitourinary (GU) cancers and how the identification of an alteration may impact precision oncology. We will provide a concise and comprehensive review of hereditary cancer genetics, and discuss genetic risk assessment, diagnosis and treatment for a range of hereditary kidney, urothelial carcinoma, prostate, and adrenal cancer syndromes. We will review current National Comprehensive Cancer Network® Guidelines for genetic evaluation of patients with kidney, upper tract, prostate, and adrenal cancers. Additional areas of focus include genetic and genomic testing technologies, interpretation of genetics and genomics test results, genetics counseling and informed consent for genetic testing. Participants will learn how to integrate genetic evaluation into their clinical practice and cancer survivorship clinic, especially in areas where clinical genetics service is not readily available.

Learning Objectives:

Describe the genetic basis of cancer susceptibility and development. Understand the difference between and genetics and genomics.
Review indications for germline genetic testing in patients with kidney, upper tract, prostate, and adrenal cancers.
Assess the goals and impact of genetic testing in patients with GU cancers and implications for family members of patients with a pathogenic germline variant.
Recognize genetic causes, tumor features and cancer risk associated with GU cancer predisposition syndromes such as Lynch and hereditary kidney cancer syndromes, and apply gained knowledge to improve care of patients.
Describe critical components of genetic risk assessment and informed consent for genetic testing.
Identify elements of genetic and genomic test reports including variant classification, variant allele frequency and clinical actionability.
Identify scenarios in which germline testing is warranted following tumor profiling/genomic testing of prostate cancer
Describe how to integrate genetics and genomic evaluation into your clinical practice and cancer survivorship clinic, especially in resource-limited areas where clinical genetics service is not readily available.